Category: Tetrahydropyrans

In an article, published in an article, once mentioned the application of 125995-03-1, Name is Atorvastatin lactone,molecular formula is C33H33FN2O4, is a conventional compound. this article was the specific content is as follows.Product Details of 125995-03-1

Gemfibrozil coadministration generally results in plasma statin area under the curve (AUC) increases, ranging from moderate (2-to 3-fold) with simvastatin, lovastatin, and pravastatin to most significant with cerivastatin (5.6-fold). Inhibition of statin glucuronidation has been postulated as a potential mechanism of interaction (Drug Metab Dispos 30:1280-1287, 2002). This study was conducted to determine the in vitro inhibitory potential of fibrates toward atorvastatin glucuronidation. [3H]Atorvastatin, atorvastatin, and atorvastatin lactone were incubated with human liver microsomes or human recombinant UDP-glucuronosyltransferases (UGTs) and characterized using liquid chromatography (LC)/tandem mass spectrometry and LC/UV/beta-radioactivity monitor/mass spectrometry. [3H]Atorvastatin yields a minor ether glucuronide (G1) and a major acyl glucuronide (G2) with subsequent pH-dependent lactonization of G2 to yield atorvastatin lactone. Atorvastatin lactonization best fit substrate inhibition kinetics (Km = 12 muM, V max = 74 pmol/min/mg, Ki = 75 muM). Atorvastatin lactone yields a single ether glucuronide (G3). G3 formation best fit Michaelis-Menten kinetics (Km = 2.6 muM, Vmax = 10.6 pmol/min/mg). Six UGT enzymes contribute to atorvastatin glucuronidation with G2 and G3 formation catalyzed by UGTs 1A1, 1A3, 1A4, 1A8, and 2B7, whereas G1 formation was catalyzed by UGTs 1A3, 1A4, and 1A9. Gemfibrozil, fenofibrate, and fenofibric acid inhibited atorvastatin lactonization with IC50 values of 346, 320, and 291 muM, respectively. Based on unbound fibrate concentrations at the inlet to the liver, these data predict a small increase in atorvastatin AUC (?1.2-fold) after gemfibrozil coadministration and no interaction with fenofibrate. This result is consistent with recent clinical reports indicating minimal atorvastatin AUC increases (?1.2- to 1.4-fold) with gemfibrozil. Copyright

Do you like my blog? If you like, you can also browse other articles about this kind. Product Details of 125995-03-1. Thanks for taking the time to read the blog about 125995-03-1

Reference£º
Tetrahydropyran – Wikipedia,
Tetrahydropyran – an overview | ScienceDirect Topics

The reaction rate of a catalyzed reaction is faster than the reaction rate of the uncatalyzed reaction at the same temperature.499-40-1, Name is (2R,3S,4R,5R)-2,3,4,5-Tetrahydroxy-6-(((2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)hexanal, molecular formula is C12H22O11. In a Article£¬once mentioned of 499-40-1, Safety of (2R,3S,4R,5R)-2,3,4,5-Tetrahydroxy-6-(((2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)hexanal

Twenty-one adducts of the form AgNO3:ER3:L (1:1:1) (E = P, As, Sb; R = Ph, cy, o-tolyl, mes; L = 2,2?-bipyridyl (‘bpy’)-based ligand), together with AgNO3:Pcy3:tpy (2:2:1) and AgNO3:PPh3:tpy (1:2:1) (‘tpy’ ? (2,2?:6,2?-terpyridine)), have been synthesized and characterized by analytical, spectroscopic (IR, far-IR, 1H and 31P NMR) and single crystal X-ray diffraction studies. The resulting complexes are predominantly of the form [(R3 E) AgL]+ NO3-, with trigonal EAgN2 coordination environments, the planarity of which is perturbed by the approach of the nitrate anion. The nitrate ion shows uni- or (semi-)bidentate coordination, excepting the complex AgNO3:P(o-tol)3:dpca (1:1:1) (dpca = bis(2-picolyl)amine) where the anion is uncoordinated, the donor dpca being a pincer-tridentate. The complex AgNO3:Pcy3:tpy (2:2:1), also reported, is dinuclear with a bridging unidentate nitrate and a terpyridine, the latter bridging through its central ring, with the peripheral rings forming chelates to either side, whereas the complex AgNO3:PPh3:tpy (1:2:1) is ionic with a five-coordinate silver, bonded to tridentate tpy and two phosphines.

Note that a catalyst decreases the activation energy for both the forward and the reverse reactions and hence accelerates both the forward and the reverse reactions.Safety of (2R,3S,4R,5R)-2,3,4,5-Tetrahydroxy-6-(((2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)hexanal, you can also check out more blogs about499-40-1

Reference£º
Tetrahydropyran – Wikipedia,
Tetrahydropyran – an overview | ScienceDirect Topics

The reaction rate of a catalyzed reaction is faster than the reaction rate of the uncatalyzed reaction at the same temperature.19752-84-2, Name is Tetrahydro-2H-pyran-3-ol, molecular formula is C5H10O2. In a Patent£¬once mentioned of 19752-84-2, Safety of Tetrahydro-2H-pyran-3-ol

The invention relates to a novel substitutive pyridine compound, and a pharmaceutically acceptable salt and a pharmaceutical preparation of the substitutive pyridine compound for regulating the activity of protein kinases and regulating signal responses between cells or in the cells. Meanwhile, the invention further relates to a pharmaceutical composition containing the compound provided by the invention, and a method for treating high proliferative diseases of mammals, especially human with the pharmaceutical composition.

The reactant in an enzyme-catalyzed reaction is called a substrate. Enzyme inhibitors cause a decrease in the reaction rate of an enzyme-catalyzed reaction.I hope my blog about 19752-84-2 is helpful to your research., Safety of Tetrahydro-2H-pyran-3-ol

Reference£º
Tetrahydropyran – Wikipedia,
Tetrahydropyran – an overview | ScienceDirect Topics

The reaction rate of a catalyzed reaction is faster than the reaction rate of the uncatalyzed reaction at the same temperature.10343-06-3, Name is 2,3,4,6-Tetra-o-acetyl-D-glucopyranose, molecular formula is C14H20O10. In a Article£¬once mentioned of 10343-06-3, Recommanded Product: 2,3,4,6-Tetra-o-acetyl-D-glucopyranose

Abstract: Conjugates of 3,4,6-tri-?-acetyl-N-acetylglucosamine and tetraacetyl glucopyranose with alkyl phosphates were synthesized. The dependence of their antibacterial and antituberculosis activities on the length of the alkyl substituent at the phosphate group was found. The conjugates with a decyl substituent exhibited in vitro the highest antituberculosis activity against Mycobacterium tuberculosis H37Rv (MIC 3?mug/mL) but the weakest effect towards Streptococcus aureus and Bacillus cereus (?MIC 125 mug/mL). Vice versa, the conjugates with a cetyl substituent demonstrated the highest antibacterial activity in vitro towards S. aureus and B. cereus (MIC 16 mug/mL) but showed the lowest antituberculosis activity (MIC 12 mug/mL) among the compounds under study.

Note that a catalyst decreases the activation energy for both the forward and the reverse reactions and hence accelerates both the forward and the reverse reactions.Recommanded Product: 2,3,4,6-Tetra-o-acetyl-D-glucopyranose, you can also check out more blogs about10343-06-3

Reference£º
Tetrahydropyran – Wikipedia,
Tetrahydropyran – an overview | ScienceDirect Topics

A catalyst don’t appear in the overall stoichiometry of the reaction it catalyzes, but it must appear in at least one of the elementary reactions in the mechanism for the catalyzed reaction. 50675-18-8, Name is Tetrahydropyran-4-carbaldehyde, molecular formula is C6H10O2. In a Article£¬once mentioned of 50675-18-8, Recommanded Product: Tetrahydropyran-4-carbaldehyde

A reliable sequence that allows for regiospecific incorporation of four alkyl substituents on an imidazole ring has been developed. This procedure involves the addition of a substituted amino alcohol to a thioamide and subsequent oxidation with PDC. Unlike many imidazole syntheses, acid-sensitive functionality is tolerated given the mild conditions.

Sometimes chemists are able to propose two or more mechanisms that are consistent with the available data.Recommanded Product: Tetrahydropyran-4-carbaldehyde, If a proposed mechanism predicts the wrong experimental rate law, however, the mechanism must be incorrect.Welcome to check out more blogs about 50675-18-8, in my other articles.

Reference£º
Tetrahydropyran – Wikipedia,
Tetrahydropyran – an overview | ScienceDirect Topics

In an article, published in an article, once mentioned the application of 134419-59-3, Name is Tetrahydro-2H-pyran-4-yl methanesulfonate,molecular formula is C6H12O4S, is a conventional compound. this article was the specific content is as follows.Recommanded Product: Tetrahydro-2H-pyran-4-yl methanesulfonate

A process for producing a 4-(un)substituted tetrahydropyran-4-carboxylic acid compound or an ester compound thereof which are represented by the formula (1): (1) (wherein R<1> represents hydrogen or a hydrocarbon group; R<2> represents hydrogen or an optionally substituted hydrocarbon group; and R<3> represents hydrogen or a hydrocarbon group), characterized by reacting a 4-(un)substituted 4-cyanotetrahydropyran compound represented by the formula (2): (2) (wherein R<1> and R<2> are the same as defined above) with water or an alcohol which are represented by the formula (3): R<3>OH (3) (wherein R<3> is the same as defined above) in the presence of an acid or base.

Do you like my blog? If you like, you can also browse other articles about this kind. Recommanded Product: Tetrahydro-2H-pyran-4-yl methanesulfonate. Thanks for taking the time to read the blog about 134419-59-3

Reference£º
Tetrahydropyran – Wikipedia,
Tetrahydropyran – an overview | ScienceDirect Topics

Chemistry is an experimental science, and the best way to enjoy it and learn about it is performing experiments.Introducing a new discovery about 65412-03-5, Name is 4-(2-Aminoethyl)tetrahydro-2H-pyran, Safety of 4-(2-Aminoethyl)tetrahydro-2H-pyran.

Benzoxazole and benzothiazole compounds and the stereoisomers, tautomers, solvates, oxides, esters, and prodrugs thereof and pharmaceutically acceptable salts thereof are disclosed. Compositions of the compounds, either alone or in combination with at least one additional therapeutic agent, with a pharmaceutically acceptable carrier, and uses of the compounds, either alone or in combination with at least one additional therapeutic agent are also disclosed. The embodiments are useful for inhibiting cellular proliferation, inhibiting the growth and/or metathesis of tumors, treating or preventing cancer, treating or preventing degenerating bone diseases such as rheumatoid arthritis, and/or inhibiting molecules such as CSF-1R.

Balanced chemical reaction does not necessarily reveal either the individual elementary reactions by which a reaction occurs or its rate law.Safety of 4-(2-Aminoethyl)tetrahydro-2H-pyran. In my other articles, you can also check out more blogs about 65412-03-5

Reference£º
Tetrahydropyran – Wikipedia,
Tetrahydropyran – an overview | ScienceDirect Topics

Application of 2081-44-9, Catalysts are substances that increase the reaction rate of a chemical reaction without being consumed in the process. 2081-44-9, Name is Tetrahydro-2H-pyran-4-ol, molecular formula is C5H10O2. In a Patent£¬once mentioned of 2081-44-9

The present invention provides compounds, compositions thereof, and methods of using the same.

The proportionality constant is the rate constant for the particular unimolecular reaction. the reaction rate is directly proportional to the concentration of the reactant. I hope my blog about 2081-44-9 is helpful to your research., Application of 2081-44-9

Reference£º
Tetrahydropyran – Wikipedia,
Tetrahydropyran – an overview | ScienceDirect Topics

A catalyst don’t appear in the overall stoichiometry of the reaction it catalyzes, but it must appear in at least one of the elementary reactions in the mechanism for the catalyzed reaction. 31608-22-7, Name is 2-(4-Bromobutoxy)tetrahydro-2H-pyran, molecular formula is C9H17BrO2. In a Patent£¬once mentioned of 31608-22-7, Computed Properties of C9H17BrO2

The specification generally relates to compounds of Formula (I): and pharmaceutically acceptable salts and prodrugs thereof, where R1, R4, R5, R6, R7, Linker, X, Y, A, G, D and E have any of the meanings defined herein. This specification also relates to the use of such compounds and pharmaceutically acceptable salts and prodrugs thereof in methods of treatment of the human or animal body, for example in prevention or treatment of cancer. This specification also relates to processes and intermediate compounds involved in the preparation of such compounds and to pharmaceutical compositions containing them.

Sometimes chemists are able to propose two or more mechanisms that are consistent with the available data.Computed Properties of C9H17BrO2, If a proposed mechanism predicts the wrong experimental rate law, however, the mechanism must be incorrect.Welcome to check out more blogs about 31608-22-7, in my other articles.

Reference£º
Tetrahydropyran – Wikipedia,
Tetrahydropyran – an overview | ScienceDirect Topics

Children learn through play, and they learn more than adults might expect. Science experiments are a great way to spark their curiosity, get their minds active, and encourage them to do something that doesn¡¯t involve a screen. 14215-68-0, C8H15NO6. A document type is Article, introducing its new discovery., Recommanded Product: N-((2S,3R,4R,5R,6R)-2,4,5-Trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-3-yl)acetamide

A simple, four-step synthesis of d-lividosamine starting from N-acetyl-d-glucosamine via a furanosyl oxazoline intermediate is described.

Interested yet? Keep reading other articles of 14215-68-0!, Recommanded Product: N-((2S,3R,4R,5R,6R)-2,4,5-Trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-3-yl)acetamide

Reference£º
Tetrahydropyran – Wikipedia,
Tetrahydropyran – an overview | ScienceDirect Topics